Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort.

Authors: Almekinders, Cornelia A. M., Lin, Lishi, Beijnen, Jos H., Sonke, Gabe S., Huitema, Alwin D. R., Dezentjé, Vincent O.

Source: Breast Cancer Research & Treatment; Feb2025, Vol. 209 Issue 3, p115-124, 10p

Adjuvant chemotherapy in small node-negative triple-negative breast cancer

Authors: Steenbruggen, Tessa G., van Werkhoven, Erik, van Ramshorst, Mette S., Dezentjé, Vincent O., Kok, Marleen, Linn, Sabine C., Siesling, Sabine, Sonke, Gabe S.

Source: In European Journal of Cancer August 2020 135:66-74

Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme

Authors: Groenland, Stefanie L., van Nuland, Merel, Bergman, Andries M., de Feijter, Jeantine M., Dezentje, Vincent O., Rosing, Hilde, Beijnen, Jos H., Huitema, Alwin D.R., Steeghs, Neeltje

Source: In European Journal of Cancer May 2020 130:32-38

Exposure–response analysis of endoxifen serum concentrations in early-breast cancer

Authors: Sanchez-Spitman, Anabel Beatriz, Moes, Dirk-Jan A. R., Swen, Jesse J., Dezentjé, Vincent O., Lambrechts, Diether, Neven, Patrick, Gelderblom, Hans, Guchelaar, Henk-Jan

Source: Cancer chemotherapy and pharmacology. 85(6):1141-1152

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100167862056.0x000001&indx=1&recIds=ETOCvdc_100167862056.0x000001

Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan.

Authors: Moes, Dirk J. A. R., Hendrikx, Jeroen J. M. A., Guchelaar, Henk-Jan, Mathijssen, Ron H. J., Bakker, J. L., Dezentjé, Vincent O., de Rouw, Nikki, van Erp, Nielka P., Smit, Egbert F., van den Heuvel, Michel M., Munnink, Thijs H. Oude, van Kats, Maartje, Croes, Sander, Kroep, Judith R., Zwaveling, Juliette, ter Heine, Rob

Source: Targeted Oncology; Sep2024, Vol. 19 Issue 5, p789-796, 8p

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD.

Authors: Knikman, Jonathan E., Zhai, Qinglian, Lunenburg, Carin A. T. C., Henricks, Linda M., Böhringer, Stefan, van der Lee, Maaike, de Man, Femke M., Offer, Steven M., Shrestha, Shikshya, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L. T., Jeurissen, Frank J. F., Portielje, Johanna E. A., Jansen, Rob L. H., Hamberg, Paul, Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter

Source: Genome Medicine; 8/15/2024, Vol. 16 Issue 1, p1-11, 11p

Subject Terms: GENETIC variation, GENOME-wide association studies, SINGLE nucleotide polymorphisms, DIHYDROPYRIMIDINE dehydrogenase, SEQUENCE analysis

A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy

Authors: Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., van Werkhoven, Erik, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, Schellens, Jan H.M.

Source: In European Journal of Cancer January 2019 107:60-67

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Authors: van Ramshorst, Mette S, van der Voort, Anna, van Werkhoven, Erik D, Mandjes, Ingrid A, Kemper, Inge, Dezentjé, Vincent O, Oving, Irma M, Honkoop, Aafke H, Tick, Lidwine W, van de Wouw, Agnes J, Mandigers, Caroline M, van Warmerdam, Laurence J, Wesseling, Jelle, Vrancken Peeters, Marie-Jeanne T, Linn, Sabine C, Sonke, Gabe S ^*

Source: In The Lancet Oncology December 2018 19(12):1630-1640

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Authors: Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, Werkhoven, Erik van, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, Schellens, Jan H M

Source: In The Lancet Oncology November 2018 19(11):1459-1467

Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study

Authors: van Ramshorst, Mette S., van Werkhoven, Erik, Honkoop, Aafke H., Dezentjé, Vincent O., Oving, Irma M., Mandjes, Ingrid A., Kemper, Inge, Smorenburg, Carolien H., Stouthard, Jacqueline M., Linn, Sabine C., Sonke, Gabe S.

Source: In The Breast October 2016 29:153-159

The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen

Authors: Sanchez-Spitman, Anabel B, Moes, Dirk-Jan AR, Gelderblom, Hans, Dezentjé, Vincent O, Swen, Jesse J, Guchelaar, Henk-Jan

Source: Pharmacogenomics. 18(12):1125-1132

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100150061620.0x000001&indx=1&recIds=ETOCvdc_100150061620.0x000001

The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity

Authors: Welzen, Marieke E. B., Dezentjé, Vincent O., van Schaik, Ron H. N., Colbers, Angela P. H., Guchelaar, Henk-Jan, van Erp, Nielka P., den Hartigh, Jan, Burger, David M., van Laarhoven, Hanneke W. M.

Source: Therapeutic drug monitoring. 37(4):501-507

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100037030649.0x000001&indx=1&recIds=ETOCvdc_100037030649.0x000001

Exposure–Response Analyses of Olaparib in Real-Life Patients with Ovarian Cancer.

Authors: Mohmaed Ali, Ma Ida, Bruin, Maaike A. C., Dezentjé, Vincent O., Beijnen, Jos H., Steeghs, Neeltje, Huitema, Alwin D. R.

Source: Pharmaceutical Research; May2023, Vol. 40 Issue 5, p1239-1247, 9p

Subject Terms: OVARIAN cancer, CANCER patients, LUTEINIZING hormone releasing hormone, OLAPARIB, PANCREATIC cancer, PROSTATE cancer, WATCHFUL waiting

Phase 1 Study to Evaluate the Safety of Reducing the Prophylactic Dose of Dexamethasone around Docetaxel Infusion in Patients with Prostate and Breast Cancer.

Authors: Lugtenberg, Rieneke T., de Groot, Stefanie, Houtsma, Danny, Dezentjé, Vincent O., Vulink, Annelie J. E., Fischer, Maarten J., Portielje, Johanneke E. A., van der Hoeven, Jacobus J. M., Gelderblom, Hans, Pijl, Hanno, Kroep, Judith R.

Source: Cancers; Mar2023, Vol. 15 Issue 6, p1691, 11p

Subject Terms: INTRAVENOUS therapy, COMBINATION drug therapy, CLINICAL trials, DEXAMETHASONE, TREATMENT effectiveness, CANCER patients, DRUG therapy, DOCETAXEL, QUALITY of life, DRUG allergy, PATIENT safety, PROSTATE tumors, BREAST tumors, EDEMA

First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC).

Authors: van der Zande, Kim, van der Noort, Vincent, Busard, Milou, Hamberg, Paul, Ras - van Spijk, Suzan, De Feijter, Jeantine, Dezentjé, Vincent O., Tascilar, Metin, Houtsma, Danny, Beeker, Aart, van den Berg, H Pieter, ten Oever, Diederik, Oving, Irma M., Zwart, Wilbert, Bergman, Andre M.

Source: Journal of clinical oncology. 39(15 suppl):5059-5059

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100174762888.0x000001&indx=1&recIds=ETOCvdc_100174762888.0x000001

Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223

Authors: Badrising, Sushil K., Louhanepessy, Rebecca D., van der Noort, Vincent, Kieffer, Jacobien, Coenen, Jules L. L. M., Hamberg, Paul, Beeker, Aart, Wagenaar, Nils, Lam, Marnix, Celik, Filiz, Loosveld, Olaf J. L., Oostdijk, Ad, Zuetenhorst, Hanneke, de Feijter, Jeantine M., Dezentjé, Vincent O., Ras-van Spijk, Suzan, Vegt, Erik, Haanen, John B., van de Poll-Franse, Lonneke V., Zwart, Wilbert, Bergman, Andries M.

Source: Prostate Cancer and Prostatic Diseases; February 2022, Vol. 25 Issue: 2 p248-255, 8p

Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study.

Authors: Benoist, Guillemette E., van Oort, Inge M., Boerrigter, Emmy, Verhaegh, Gerald W., van Hooij, Onno, Groen, Levi, Smit, Frank, de Mol, Pieter, Hamberg, Paul, Dezentjé, Vincent O., Mehra, Niven, Gerritsen, Winald, Somford, Diederik M., van Erp, Nielka P. H., Schalken, Jack A.

Source: Clinical Chemistry; Jun2020, Vol. 66 Issue 6, p842-851, 10p

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

The effect of rs5758550 on CYP2D62phenotype and formation of endoxifen in breast cancer patients using tamoxifen

Authors: Sanchez-Spitman, Anabel B, Moes, Dirk-Jan AR, Gelderblom, Hans, Dezentjé, Vincent O, Swen, Jesse J, Guchelaar, Henk-Jan

Source: Pharmacogenomics; August 2017, Vol. 18 Issue: 12 p1125-1132, 8p